Fig. 1: Tumor subtyping and PFS in patients from PALOMA-2. | npj Breast Cancer

Fig. 1: Tumor subtyping and PFS in patients from PALOMA-2.

From: Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies

Fig. 1

a Pie charts of subtype distributions by HTG-AIMs, HTG-PAM50.sgPct, and ruoProsigna-PAM50 subtyping methods among total available samples. HTG-AIMS and HTG-PAM50.sgPct were applied on the entire cohort of 455 samples; only 222 samples were available for ruoProsigna-PAM50. b Kaplan–Meier curves of median PFS by subtype and treatment in PALOMA-2 with ruoProsigna-PAM50, the gold standard. c Hazard ratios and 95% CIs for PFS by breast cancer subtype and subtyping method in PALOMA-2; for HGT-AIMS analysis, six patients were not included (four NL and two BL). *Data from Finn et al.17. LET letrozole, N number of patients in the analysis group, n number of patients, NA not available, PAL palbociclib, PBO placebo.

Back to article page